

Supporting Information

Metal-free synthesis of imidazopyridine from nitroalkene and 2-aminopyridine in the presence of catalytic iodine and aqueous hydrogen peroxide

Yuma Tachikawa, Yoshitomo Nagasawa, Sohei Furuhashi, Lei Cui, Eiji Yamaguchi, Norihiro Tada, Tsuyoshi

Miura, Akichika Itoh*

Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan

E-mail: itoha@gifu-pu.ac.jp

1.	General Information	SI-2
2.	General Procedure	SI-2
Appendix: ^1H and ^{13}C spectra		SI-5

1. General Information.


All dry solvents were obtained from Kanto Kagaku Co., Ltd. Other chemicals used were of reagent grade and were obtained from Tokyo Kasei Kogyo Co., Ltd., Sigma-Aldrich Co., Ltd., Wako Pure Chemical Industries, Ltd., Kishida Chemical Co., Ltd., and Nacalai Tesque. ^1H NMR and ^{13}C NMR spectra were obtained on a JEOL ECA 500 (500 MHz for ^1H NMR and 125 MHz for ^{13}C NMR). Chemical shifts (δ) are reported in parts per million (ppm) downfield from internal Me₄Si. Preparative thin-layer chromatography (TLC) was carried out on precoated plates of silica gel (MERCK, silica gel F-254, YMC-GEL (8 nm S-25 μm)).

2. General Procedure

Synthesis of 3-Nitro-2-phenylimidazo[1,2-*a*]pyridine (3a) (Table 2):


A solution of *trans*- β -nitrostyrene (**1a**)(44.7 mg, 0.3 mmol), 2-aminopyridine (**2a**)(33.9 mg, 1.2 equiv), iodine (7.6 mg, 0.1 equiv), and 35% aq. H₂O₂ (106 μl , 4 equiv) in DMSO (3 mL) in a pyrex test tube was stirred under air at 70 °C for 20 h. The reaction mixture was washed with aq. Na₂S₂O₃ and H₂O, and extracted with EtOAc. Organic layer was dried over MgSO₄, and concentrated *in vacuo*. Purification of the crude product by flash chromatography on silica gel (hexane : EtOAc = 2 : 1) provided 3-nitro-2-phenylimidazo[1,2-*a*]pyridine (**3a**) (54 mg, 75%).

3-Nitro-2-phenylimidazo[1,2-*a*]pyridine (3a)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl₃): δ 9.49 (d, J = 7.5 Hz, 1 H), 7.91–7.88 (m, 2 H), 7.82 (d, J = 9.2 Hz, 1 H), 7.65–7.62 (m, 1 H), 7.50 (t, J = 3.2 Hz, 3 H), 7.28 (t, J = 6.9 Hz, 1 H); ^{13}C NMR (125 MHz, CDCl₃): δ 150.2, 145.0, 131.8, 130.8, 130.1, 129.9, 128.0, 118.2, 116.4; CAS Registry Number: 67292-98-2

2-(4-Chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3b)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl₃): δ 9.51 (d, J = 6.9 Hz, 1 H), 7.88–7.83 (m, 3 H), 7.68 (t, J = 8.1 Hz, 1 H), 7.48 (d, J = 8.6 Hz, 2 H), 7.31–7.27 (m, 1 H); ^{13}C NMR (125 MHz, CDCl₃): δ 149.0, 145.1, 136.4, 131.5, 131.0, 130.2, 128.4, 128.2, 118.3, 116.7; CAS Registry Number: 34165-02-1

2-(4-Bromophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3c)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl₃) δ 9.51 (d, J = 6.9 Hz, 1 H), 7.85–7.79 (m, 3 H), 7.69–7.63 (m, 3 H), 7.32–7.29 (m, 1 H); ^{13}C NMR (125 MHz, CDCl₃) δ 149.0, 145.1, 131.7, 131.4, 131.1, 130.7, 128.2, 124.8, 118.3, 116.7; CAS Registry Number: 1312318-90-3

3-Nitro-2-p-tolylimidazo[1,2-*a*]pyridine (3d)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl₃) δ 9.51 (d, J = 6.9 Hz, 1 H), 7.83 (d, J = 8.0 Hz, 3 H), 7.64 (t, J = 7.5 Hz, 1 H), 7.32–7.24 (m, 3 H), 2.44 (s, 3 H); ^{13}C NMR (125 MHz, CDCl₃) δ 150.4, 145.1, 140.5, 130.8, 130.0, 129.0, 128.9, 128.2, 118.2, 116.3, 21.5; CAS Registry Number: 1355334-02-9

2-(4-Methoxyphenyl)-3-nitroimidazo[1,2-*a*]pyridine (3e)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl_3) δ 9.50 (d, $J = 6.9$ Hz, 1 H), 7.94 (d, $J = 8.5$ Hz, 2 H), 7.80 (d, $J = 9.1$ Hz, 1 H), 7.64 (t, $J = 8.1$ Hz, 1 H), 7.25 (dd, $J = 18.3, 6.6$ Hz, 1 H), 7.02 (d, $J = 8.6$ Hz, 2 H), 3.89 (s, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 161.2, 150.2, 145.2, 131.8, 130.9, 128.2, 124.0, 118.0, 116.2, 113.5, 55.3; CAS Registry Number: 956077-87-5

2-(3-Chlorophenyl)-3-nitroimidazo[1,2-a]pyridine (3f)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl_3) δ 9.52 (d, $J = 7.4$ Hz, 1 H), 7.91–7.80 (m, 3 H), 7.70–7.67 (m, 1 H), 7.49–7.43 (m, 2 H), 7.33–7.30 (m, 1 H); ^{13}C NMR (125 MHz, CDCl_3) δ 148.6, 145.1, 134.1, 133.6, 131.1, 130.2, 130.0, 129.4, 128.3, 128.1, 118.4, 116.8; CAS Registry Number: 1355334-06-3

2-(2-Chlorophenyl)-3-nitroimidazo[1,2-a]pyridine (3g)¹ (Table 2)




yellow viscous oil; ^1H NMR (500 MHz, CDCl_3) δ 9.52 (d, $J = 6.9$ Hz, 1 H), 7.88 (d, $J = 9.2$ Hz, 1 H), 7.69 (t, $J = 7.8$ Hz, 1 H), 7.55–7.53 (m, 2 H), 7.47–7.39 (m, 2 H), 7.34 (t, $J = 6.9$ Hz, 1 H); ^{13}C NMR (125 MHz, CDCl_3) δ 147.3, 145.0, 134.0, 131.9, 130.9, 130.8, 130.7, 129.5, 127.8, 126.7, 118.5, 116.8; CAS Registry Number: 1355334-05-2

6-Methyl-3-nitro-2-phenylimidazo[1,2-a]pyridine (3h)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl_3) δ 9.29 (s, 1 H), 7.89–7.87 (m, 2 H), 7.70 (d, $J = 9.2$ Hz, 1 H), 7.49–7.46 (m, 4H), 2.48 (s, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 150.0, 144.0, 133.6, 132.0, 129.9, 129.8, 128.0, 126.8, 126.0, 117.3, 18.6; CAS Registry Number: 1355334-14-3

6-Chloro-3-nitro-2-phenylimidazo[1,2-a]pyridine (3i)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl_3) δ 9.55 (d, $J = 1.7$, 1 H), 7.89–7.86 (m, 2 H), 7.76 (d, $J = 9.2$, 1 H), 7.60 (dd, $J = 9.5, 2.2$ Hz, 1 H), 7.51–7.48 (m, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 150.2, 143.2, 132.0, 131.3, 130.3, 130.0, 128.1, 126.0, 124.9, 118.4; CAS Registry Number: 1355334-16-5

Ethyl 3-nitro-2-phenylimidazo[1,2-a]pyridine-7-carboxylate (3j)¹ (Table 2)




yellow solid; ^1H NMR (500 MHz, CDCl_3) δ 9.50 (d, $J = 7.5$ Hz, 1 H), 8.48 (s, 1 H), 7.92–7.89 (m, 2 H), 7.82 (dd, $J = 7.5, 1.7$ Hz, 1 H), 7.53–7.51 (m, 3 H), 4.48 (q, $J = 7.5$ Hz, 2 H), 1.46 (t, $J = 7.5$ Hz, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 163.7, 150.8, 144.2, 132.1, 131.4, 130.4, 130.0, 128.2, 127.8, 120.0, 115.4, 62.4, 14.2; CAS Registry Number: 1355334-17-6

8-Methyl-3-nitro-2-phenylimidazo[1,2-a]pyridine (3k)¹ (Table 2)



yellow solid; ^1H NMR (500 MHz, CDCl_3) δ 9.34 (d, $J = 6.9$ Hz, 1 H), 7.91–7.89 (m, 2 H), 7.51–7.48 (m, 3 H), 7.43 (d, $J = 6.9$ Hz, 1 H), 7.16 (t, $J = 6.9$ Hz, 1 H), 2.71 (s, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 149.6, 145.1, 132.1, 130.0, 129.9, 129.8, 128.5, 128.0, 125.8, 116.4, 16.5; CAS Registry Number: 1355334-10-9

6-Methyl-2-(4-Chlorophenyl)-3-nitroimidazo[1,2-a]pyridine (3l) (Table 2)



yellow solid; mp 187-188 °C; ^1H NMR (500 MHz, CDCl_3) δ 9.30 (s, 1 H), 7.85 (d, J = 8.6 Hz, 2 H), 7.72 (d, J = 9.2 Hz, 1 H), 7.51 (d, J = 9.2 Hz, 1 H), 7.45 (d, J = 8.6 Hz, 2 H), 2.51 (s, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 148.8, 144.1, 136.1, 133.8, 131.3, 130.4, 128.3, 127.1, 126.1, 117.4, 18.6; HRMS (DART, positive) calcd for $\text{C}_{14}\text{H}_{10}\text{ClN}_3\text{O}_2$ [M + H]⁺ 288.05398,

Found 288.05225.

Reference

- (1) Yan, R.; Yan, H.; Ma, C.; Ren, Z.; Gao, X.; Huang, G.; Liang, Y. *J. Org. Chem.* **2012**, 77, 2024.




Fig. 1: ^1H NMR of 3-nitro-2-phenylimidazo[1,2-*a*]pyridine (3a)




Fig. 2: ^{13}C NMR of 3-Nitro-2-phenylimidazo[1,2-*a*]pyridine (3a)




Fig. 3: ^1H NMR of 2-(4-chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3b)




Fig. 4: ^{13}C NMR of 2-(4-chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3b)




Fig. 5: ^1H NMR of 2-(4-bromophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3c)




Fig. 6: ^{13}C NMR of 2-(4-bromophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3c)




Fig. 7: ^1H NMR of 3-nitro-2-p-tolylimidazo[1,2-a]pyridine (3d)




Fig. 8: ^{13}C NMR of 3-nitro-2-p-tolylimidazo[1,2-a]pyridine (3d)




Fig. 9: ^1H NMR of 2-(4-methoxyphenyl)-3-nitroimidazo[1,2-*a*]pyridine (3e)




Fig. 10: ^{13}C NMR of 2-(4-methoxyphenyl)-3-nitroimidazo[1,2-*a*]pyridine (3e)





Fig. 11: ^1H NMR of 2-(3-chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3f)





Fig. 12: ^{13}C NMR of 2-(3-chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3f)




Fig. 13: ^1H NMR of 2-(2-chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3g)




Fig. 14: ^{13}C NMR of 2-(2-chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3g)




Fig. 15: ^1H NMR of 6-methyl-3-nitro-2-phenylimidazo[1,2-*a*]pyridine (3h)




Fig. 16: ^{13}C NMR of 6-methyl-3-nitro-2-phenylimidazo[1,2-*a*]pyridine (3h)




Fig. 17: ¹H NMR of **6-chloro-3-nitro-2-phenylimidazo[1,2-*a*]pyridine (3i)**




Fig. 18: ¹³C NMR of **6-chloro-3-nitro-2-phenylimidazo[1,2-*a*]pyridine (3i)**




Fig. 19: ^1H NMR of ethyl 3-nitro-2-phenylimidazo[1,2-*a*]pyridine-7-carboxylate (3j)




Fig. 20: ^{13}C NMR of ethyl 3-nitro-2-phenylimidazo[1,2-*a*]pyridine-7-carboxylate (3j)




Fig. 21: ^1H NMR of **8-methyl-3-nitro-2-phenylimidazo[1,2-*a*]pyridine (3k)**




Fig. 22: ^{13}C NMR of **8-methyl-3-nitro-2-phenylimidazo[1,2-*a*]pyridine (3k)**




Fig. 23: ^1H NMR of 6-methyl-2-(4-chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3l)




Fig. 24: ^{13}C NMR of 6-methyl-2-(4-chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3l)